Simon Husby
Overview
Explore the profile of Simon Husby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyvsgaard E, Grauslund M, Sjo L, Melchior L, Grantzau T, Gjerdrum L, et al.
Am J Hematol
. 2025 Jan;
100(4):712-716.
PMID: 39865309
No abstract available.
2.
Husby S, Tulstrup M, Harslof M, Nielsen C, Haastrup E, Ebbesen L, et al.
Leukemia
. 2024 Sep;
38(11):2456-2465.
PMID: 39223296
Mosaic chromosomal alterations (mCAs) in hematopoietic cells increase mortality and risk of hematological cancers and infections. We investigated the landscape of mCAs and their clinical consequences in 976 patients with...
3.
Baech J, Husby S, Trab T, Kragholm K, Brown P, Gorlov J, et al.
Br J Haematol
. 2023 Dec;
204(3):967-975.
PMID: 38155503
Cardiovascular diseases, especially congestive heart failure (CHF), are known complications of anthracyclines, but the risk for patients undergoing high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) is not well established....
4.
Kyvsgaard E, Riley C, Clausen M, Harslof M, Heftdal L, Niemann C, et al.
Br J Haematol
. 2023 Oct;
204(1):356-360.
PMID: 37830381
No abstract available.
5.
Trab T, Baech J, Jakobsen L, Husby S, Severinsen M, Eloranta S, et al.
Lancet Haematol
. 2023 Sep;
10(10):e838-e848.
PMID: 37689081
Background: Second primary malignancies (SPMs) are known complications after chemotherapy, but the risk is not well characterised for patients with lymphoma treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation...
6.
Salim R, Husby S, Eskelund C, Scott D, Holte H, Kolstad A, et al.
Leuk Lymphoma
. 2023 Jun;
64(8):1414-1423.
PMID: 37259807
Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous disease, emphasizing the need for prognostic biomarkers. In this study we aimed at comparing the prognostic value of two RNA-based...
7.
Gerdtsson A, de Matos Rodrigues J, Eskelund C, Husby S, Gronbaek K, Raty R, et al.
Haematologica
. 2022 Dec;
108(4):1092-1104.
PMID: 36519324
The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL International Prognostic Index (MIPI), high proliferation (Ki-67), non-classic...
8.
Husby S, Baech-Laursen C, Eskelund C, Favero F, Jespersen J, Hutchings M, et al.
Leukemia
. 2022 Oct;
36(12):2912-2916.
PMID: 36274067
No abstract available.
9.
Dahl M, Husby S, Eskelund C, Besenbacher S, Fjelstrup S, Come C, et al.
Leukemia
. 2022 Feb;
36(4):1198.
PMID: 35181760
No abstract available.
10.
Husby S, Jorgensen G, Favero F, Jespersen J, Rodriguez-Gonzalez F, Nielsen C, et al.
Bone Marrow Transplant
. 2022 Feb;
57(4):674-677.
PMID: 35124694
No abstract available.